**PRODUCT PIPELINE**

**IMiDs® Compounds:**
- REVlimid®: Multiple Myeloma (US)  
- REVlimid®: MDS deletion 5q (US)  
- REVlimid®: Multiple Myeloma (EMEA)  
- REVlimid®: MDS deletion 5q (EMEA)  
- REVlimid®: Multiple Myeloma (SWISS)  
- REVlimid®: MDS deletion 5q (SWISS)  
- REVlimid®: MDS  
- REVlimid®: CLL  
- REVlimid®: NHL  
- REVlimid®: Solid Tumors  
- pomalidomide (CC-4047): Myelofibrosis  
- pomalidomide (CC-4047): Multiple Myeloma  
- pomalidomide (CC-4047): Solid Tumors  
- pomalidomide (CC-4047): Sickle Cell Anemia  
- CC-11006: MDS  
- CC-10015: Rheumatology  
- CC-16057: Oncology/Inflammation

**THALOMID®:**
- Multiple Myeloma (US)  
- ENL

**Thalidomide Pharmion 50 MG:**
- Multiple Myeloma (EMEA)  
- Other Cancer

**VIDAZA® (azacitidine):**
- MDS (US)  
- MDS (EMEA)  
- AML  
- Solid Tumors  
- MDS/AML (Oral azacitidine)

**ALKERAN®:**
- Multiple Myeloma/Ovarian Cancer

**Ritalin®/FOCALIN™:**
- FOCALIN: ADHD  
- Ritalin LA®: ADHD  
- FOCALIN XR™: ADHD

**Anti-Inflammatory:**
- apremilast (CC-10006): Psoriasis  
- apremilast (CC-10004): Psoriatic Arthritis  
- apremilast (CC-10004): Behcet's Syndrome  
- CC-11050: Inflammatory

**Kinase Inhibitors:**
- JNK 930: Fibrotic Diseases

**Ligase Inhibitors:**
- Ubiquitin Ligase: Cancer

**Stem Cells and Tissue Products:**
- Lifebank USA: Private Stem Cell Banking  
- HPP: Transplants  
- PDA-001: Autoimmune/Cancer  
- BIOVANCE and Acebagraft™

**MGCD0103:**
- Solid Tumors (w/ gemcitabine)  
- Hematologic Malignancies  
- w/ Vida in MDS/AML  
- w/ Vida in lymphoma

**AMRUBICIN®:**
- SCLC  
- w/ Cisplatin for SCLC  
- Breast Cancer

**ACTIVIN INHIBITOR**
- ACE-011: Cancer-related bone loss

---

The products represented in this development and found in the product pipeline are intended for investors and members of the media to provide general information on Celgene. This information is not represented to be a complete description and is subject to change without notice. Celgene Corporation may from time to time update this information but does not warrant that it will take place at any particular time nor assume any obligation to update this information.